List of Contract Research Companies in New Jersey - 23

AcceGen Biotech proudly develops innovative technologies for the pharmaceutical, biotech and specialty ingredients markets. We are committed to supplying the best products and services with global manufacturing, development expertise and advanced technologies to enhance the overall quality of life. AcceGen Biotech developed significant expertise in cell and genomic research. We provide a variety of high-quality human/animal cells, cell media/kits, cell-derived molecular biology products, gene-based assay kits, Clones, Fish probes and Sequencing products for research use. AcceGen Biotech offers custom cell line generation, microRNA sponges and microRNA Agomir/Antagomir services to simplify the gene research. The aim is to accelerate scientific discovery related to genetic analysis available to academic researchers as well as commercial enterprises. AcceGen Biotech has permanent facilities in Fairfield (New Jersey). We take care of our customers and their global, regional or local requirements. We welcome potential partners and distributors to explore our business all over the world.

Adare Pharma Solutions is a global technology-driven CDMO providing end-to-end integrated services, from product development through commercial manufacturing and packaging, with expertise focusing on oral dosage forms for the Pharmaceutical industry. Adare's specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions. With a proven history in drug delivery, Adare has developed and manufactures more than 45 products sold by customers worldwide.

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Based in North Brunswick, New Jersey, Ascendia Pharmaceuticals is a specialty contract development and manufacturing (CDMO) company dedicated to delivering sophisticated formulations of existing drug products, and enabling formulations for preclinical- and clinical-stage drug candidates. Ascendia Pharmaceuticals is your ideal partner for: · Early stage IND-enabling formulations for toxicology and pharmacokinetic (PK) studies · Rapid development through Phase I CTM materials for oral and parenteral dosage forms · Fast discovery formulation support · Formulation development and CTM manufacturing for specialty pharmaceuticals Ascendia Pharmaceuticals also provides special development programs: · Formulations for poorly soluble and low bioavailability drugs · First-in-man injectable formulations · Nano-emulsion and nano-particle formulations · Peptide formulations · Sustained release by parenteral or oral routes · Development of 505(b)(2) products · Development of complex generics · High potency and DEA controlled drug substances · Ocular formulation development · Animal health formulations

AustarPharma is a pharmaceutical company that specializes in drug delivery technologies.

BASF Corporation is the largest affiliate of BASF SE and the second largest producer and marketer of chemicals and related products in North America. BASF creates chemistry for a sustainable future. They combine economic success with environmental protection and social responsibility.BASF Corporation operates more than 100 production and research and development sites throughout North America and operates Verbund sites in Geismar, Louisiana and Freeport, Texas. At Verbund sites, production plants, energy and material flows, logistics, and site infrastructure are all integrated.

At Castor, we believe in the power of clinical research and the power of technology. And we know that together, these forces can help extend human healthspan. To achieve this reality, we must make patient-centered clinical trials a possibility for everyone, anywhere in the world. That's why we are using technology to capture the world's research data and optimize each activity of a clinical trial. From recruitment to monitoring, our modular clinical trial platform makes it easier to design and deploy trials, enroll and engage patients, collect data and analyze results. Each module can be used individually or in unison with others, providing the ability to customize each solution to fit your needs, and grow at your own pace. That's delightful for patients, effortless for study teams, risk-free for sponsors.

Established in 2010, Crystal Pharmatech is a specialized CRO/CDMO, excelling in crystal form and formulation services. Our exceptional track record includes supporting 1,000 clients and collaborating on over 2,000 compounds, showcasing our expertise in solid-state research, crystallization, pre-formulation, formulation development, and manufacturing. With a global presence encompassing three strategically located R&D centers in New Jersey (USA), Toronto (Canada), and Suzhou (China), we are powered by a skilled team of around 250 professionals. As a leader in both conventional and enabling formulation technologies, including amorphous solid dispersion, we take pride in our cGMP facilities, strictly adhering to the rigorous standards set by the FDA, EMA, and NMPA. Our integrated service encompasses the entire new drug development journey, from developability assessment and solid form screening to pre-formulation, formulation development, and CTM and commercial manufacturing. Introducing our pioneering Mol2Med program, designed to expedite small molecule lead compounds or preclinical candidates into Phase I and beyond, with unparalleled efficiency and precision. This 3-step First-Time-Right approach begins at the lead optimization/PCC stage: Step 1: Developability Assessment to guide API form selection and formulation design. Step 2: Solid form screening/selection and Preformulation. Step 3: Formulation development and CTM manufacturing, including packaging, labeling, and shipping to the clinical site. This innovative approach guarantees a robust API form and a scalable manufacturing process, culminating in a First-Time-Right formulation for Phase I. Streamlining the transition to future clinical studies upon Phase I success, our First-Time-Right approach sets the foundation for optimized drug development and success beyond.

Emcure Pharmaceuticals Ltd. (EPL) is an Indian pharmaceutical company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Established in 1981, EPL is ranked as the 11th largest company in Indian Pharmaceutical Market as per AWACS MAT Feb'24 data.

Evergreen Theragnostics was established in 2019 to be a leading US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO). Our team’s expertise and track record in theragnostic radiopharmaceutical commercialization, manufacturing process development, and regulatory affairs management, make us your ideal partner for all of your radiopharmaceutical development, manufacturing, and commercialization needs.

Frontage Laboratories, Inc. is a CRO that provides integrated, science-driven, product development services throughout the drug discovery and development process to enable pharmaceutical and biotechnology companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of molecules through development and file regulatory submissions in the United States, China and other countries around the world.

Genesis Drug Discovery and Development (GD3), a member of Genesis Global Group, is a contract research organization focused on providing services to support preclinical drug development programs from discovery to candidate selection. Our diversified portfolio of services covers all the areas of preclinical drug discovery/development including Discovery Biology, Chemistry, DMPK/in-vivo pharmacology and Toxicology. The portfolio spans a wide range of therapeutic areas include oncology, ocular, inflammation, metabolic diseases, ​and microbiome.

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 200,000 customers from over 100+ countries and regions worldwide have used GenScript's premier, convenient, and reliable products and services. GenScript has over 6,900 employees globally, with about 10% R&D personnel. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis, and bioinformatics, including more than 300 patents and about 900 patent applications. As of December 31, 2023, GenScript's products and services have been cited by 87,745 scientific papers worldwide. GenScript is committed to striving toward its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.

Integrated Analytical Solutions, Inc. (IAS), a Genesis Drug Discovery and Development (GD3) Company, is a contract research organization that provides analytical, bioanalytical and drug metabolism services to the pharmaceutical industry. The company was founded in 2004 to fill an unmet need for expert, economical and timely analytical services. Our laboratory is a state-of-the-art facility located in Berkeley, California within one of the world's most active life science research clusters (San Francisco Bay Area). The company is comprised of two operating divisions: GxP and Research and Discovery (R&D). The separate divisions enable the company to accommodate a wide range of projects and deliver fit-for-purpose methods based on each client's specific stage of development and budget. IAS offers each and every client boutique-level attention while providing cost-effective and timely data. Our track record for outstanding service and our collaborative spirit have resulted in long-lasting relationships with biopharmaceutical groups and academic laboratories around the globe.

Interpace Biosciences develops molecular diagnostic tests under the brand Interpace Diagnostics, and provides clincal trial services under the brand Interpace PharaSolutions.

J-STAR Research, Inc. is a contract chemistry organization serving as an outsourcing partner for the pharmaceutical and biotechnology industries. J-STAR is a leading provider of services in organic synthesis problem solving, early phase non-GMP and GMP manufacturing and crystallization R&D. While high quality synthetic chemistry and process research services continue to be J-Star’s foundation, the company has steadily added and continues to expand in the areas of QC, GMP and QA, Crystallization R&D, Solid Form and Polymorph Screening, Catalysis Screening + Enabling Technology, Highly Potent Compound Handling (HPAPI), Impurity Isolation and Structural Elucidation by NMR and HR-LC/MS and Preformulation for Drug Product Development. J-Star’s expert team of scientists and professionals coupled with solid industrial experience, a track record of dependability, and over 70,000 SF of well-equipped laboratories across two New Jersey research facilities ensures that all projects are delivered in full, on time and with rigorous quality.

MedChemExpress LLC, or MedChemExpress (MCE), is a biotech company based in New Jersey, USA, with locations in Princeton and Monmouth Junction. The company specializes in supplying high-quality research chemicals and biochemicals, including a vast selection of bioactive molecules such as selective inhibitors and recombinant proteins. These products are essential for pharmaceutical and life sciences research. MCE offers a variety of services to support research and development in the life sciences sector. Their services include custom synthesis for various compounds, protein expression and purification, and a comprehensive compound screening platform. They also provide molecular biology tools and cell biology services, which encompass cell culture and analysis. With a catalog of over 50,000 products, MedChemExpress is recognized for its contributions to drug discovery and research, serving a diverse global customer base in academia and industry.

Nth Analytics pharmaceuticals consultants: CDISC SDTM/ADaM, biostatistics, and SAS programming.

Based on RUCDR Infinite Biologics, which was founded in 1999 to provide biobanking services and biomaterials to advance the genetic disease research of partners in the public and private sectors. Following the spinout, Infinity Biologix said it will provide sample collection, processing, storage, and analytical services integrated with scientific and technical support in both the research and clinical arenas.COVID-19: COVID-19 Saliva test. In April 2020, IBX (formerly Rutgers RUCDR Infinite Biologics) received the first FDA Emergency Use Authorization (EUA) enabling the use of saliva tests to detect the presence of the SARS-CoV-2 coronavirus. Since then, a revised EUA for anat-home saliva sample collectionwas also approved.

Sannova is a boutique CRO with a unique Z factor approach, prioritizing high standards and exceptional services for clients. We offer fast, personalized, end to end analytical and bioanalytical services for complex, novel, and generic therapeutics. Our core values of quality, speed, and flexibility enable us to deliver exceptional results via our passionate team of expert scientists. Our commitment to reliable and reproducible results gives clients confidence in their therapeutic development.

Tara Innovations LLC is formulation contract research organization (CRO). We specialize in product development, technology management, analysis, and process development. We do preformulation and pharmaceutical consulting. We are expert in nanotechnology.

WCG is a true partner to research sponsors, CROs, sites and participants in navigating the clinical research journey. The pioneer of independent ethical review, now the industry gold standard, WCG's 55-year legacy of independent review solutions serves as the foundation on which we continually build to accelerate and improve the clinical research journey. We lead the way by reimagining processes, optimizing quality and safety, strengthening productivity, and pioneering new solutions that leverage data and technology to accelerate research and impact global health. WCG liberates study stakeholders from the constraints that risk trial efficacy while improving quality outcomes and efficiency through the process. Ninety percent of all clinical trials leverage our knowledge, highly specialized solutions, and data-driven insights to mitigate risk today for a more promising tomorrow.